# US 2013/0252953 A1 · Targeting Human Thymidylate Kinase Induces DNA Repair Toxicity in Malignant Tumor Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252953 A1
- Document ID: US20130252953A1
- Status: Published application
- Kind: A1
- Application number: 13/990,398
- Filed: 2011-11-29
- Published: 2013-09-26
- Earliest claimed: 2010-11-29
- Assignees: National Yang-Ming University; National Taiwan University
- Inventors: Zee-Fen Chang; Jim-Min Fang; Chun-Mei Hu; Ming-Tyng Yeh
- Web page: https://patentgrep.com/patent/US20130252953A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/425: Thiazoles
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 275/04: condensed with carbocyclic rings or ring systems
- C07D 275/06: with hetero atoms directly attached to the ring sulfur atom
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel TMPK inhibitor compositions and their methods of use. In particular, it relates to novel TMPK inhibitor compositions and therapeutics that lead to dUTP-mediated DNA repair in tumor cells and acts as a novel chemosensitizer, which are useful in methods for treating or preventing cancers.

## Claims

### Claim 1

A composition for inhibiting thymidylate kinase (TMPK) comprising a therapeutically effective amount of formula (I):
wherein
X═CH or N;
Y═S, SO2, O, C═O, or NR5, wherein R5 is a substituent selected from the group consisting of hydrogen, a straight, branched or cyclic alkyl group, aralkyl, heteroaralkyl, heteroarakenyl, aryl, heteroaryl, optionally substituted with one or more substituents such as halogen, alkyl, hydroxyl, alkoxy, amino, nitro, cyano and carbonyl;
R1═(CH2)nCOR6, wherein n is 0, 1, 2, or 3; and
R2, R3, R4 and R6 are substituents independently selected from the group consisting of hydrogen, a straight, branched or cyclic alkyl group, a straight, branched or cyclic alkenyl group, a straight, branched or cyclic alkoxyl group, fluoroalkyl, perfluoroalkyl, aralkyl, arakenyl, arakynyl, heteroaralkyl, heteroarakenyl, heteroarakynyl, aryl, heteroaryl, optionally substituted with one or more substituents such as halogen, alkyl, hydroxyl, alkoxy, amino, nitro, cyano and carbonyl;
or a pharmaceutically acceptable salt, hydrate or solvate thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The composition of claim 1, wherein formula (I) is:

### Claim 4 (depends on 1)

The composition of claim 1, wherein formula (I) is at least one of the following:

### Claim 5 (depends on 1)

The composition of claim 1, wherein formula (I) is at least one of the following:

### Claim 6 (depends on 1)

The composition of claim 1, wherein formula (I) is:

### Claim 7 (depends on 1)

The composition of claim 1, wherein formula (I) is at least one of the following:

### Claim 8 (depends on 1)

The composition of claim 1, wherein formula is:

### Claim 9 (depends on 1)

The composition of claim 1, wherein formula (I) is at least one of the following:

### Claim 10 (depends on 1)

The composition of claim 1, wherein formula (I) is at least one of the following:

### Claim 11 (depends on 1)

The composition of claim 1, wherein formula (I) is:

### Claim 12 (depends on 1)

The composition of claim 1, wherein formula (I) is:

### Claim 13 (depends on 1)

The composition of claim 1, wherein formula (I) is at least one of the following:

### Claim 14 (depends on 1)

The composition of claim 1, wherein said composition is capable of inhibiting TMPK activity.

### Claim 15 (depends on 1)

The composition of claim 1., wherein said composition is capable of inhibiting cellular dTTP levels.

### Claim 16 (depends on 1)

The composition of claim 1, wherein said composition is capable of inhibiting tumor growth, DNA damage checkpoint, DNA mismatch repair, nucleotide excision repair, double-strand break repair, DNA helicase function, signaling, cell cycle control or apoptosis.

### Claim 17 (depends on 16)

The composition of claim 16, wherein said double-strand break repair is associated with radiation therapy, chemotherapy or immunomodulatory therapy.

### Claim 18 (depends on 17)

The composition of claim 17, wherein said chemotherapy involves treatment with doxorubicin.

### Claim 19 (depends on 1)

The composition of claim 1, wherein said composition selectively targets toxicity to cancer cells with DNA lesions.

### Claim 20 (depends on 1)

The composition of claim 1, wherein said composition is capable of sensitizing cancer cells to radiation therapy, chemotherapy or immunomodulatory therapy.

### Claim 21 (depends on 20)

The composition of claim 20, wherein said chemotherapy involves treatment. with doxorubicin.

### Claim 22 (depends on 1)

The composition of claim 1, wherein said composition does not result in genotoxic side effects.

### Claim 23 (depends on 1)

The composition of claim 1, wherein said composition exhibits an IC50 value of about 10 μM or less.

### Claim 24 (depends on 1)

The composition of claim 1, wherein said composition exhibits an IC50 value of about 5 μM or less.

### Claim 25 (depends on 1)

The composition of claim 1, wherein said composition exhibits an IC50 value of about 1 μM or less.

### Claim 26 (depends on 1)

The composition of claim 1, wherein said composition exhibits an IC50 value of about 0.5 μM or less.

### Claim 27 (depends on 1)

The composition of claim 1, wherein said composition exhibits an IC50 value of about 0.25 μM or less.

### Claim 28 (depends on 1)

The composition of claim 1, wherein said composition exhibits an IC50 value of about 0.1 μM or less.

### Claim 29 (depends on 1)

The composition of claim 1, wherein said composition is administered once daily for 3 consecutive days

### Claim 30 (depends on 1)

The composition of claim 1, wherein said composition is administered one to two times per day.

### Claim 31 (depends on 1)

The composition of claim 1, wherein said composition is administered at a dose of about 5 mg/kg to about 30 mg/kg.

### Claim 32 (depends on 1)

A pharmaceutical composition comprising a composition of claim 1 and a pharmaceutically acceptable carrier.

### Claim 33 (depends on 1)

A method for manufacturing a composition of claim 1 comprising the steps:
(a) treating 2-chloro-6-methylnicotinonitrile (or 2-chloro-4,6-dimethylnicotinonitrile with thiourea to give intermediate compound of 2-mercapto-6-methylnicotinonitrile (or 2-mercapto-4,6-dimethylnicotinonitrile);
(b) treating 2-mercapto-6-methylnicotinonitrile and 2-mercapto-4,6-dimethylnicotinonitrile in concentrated H2SO4 at 100° C. to give pyridinoisothiazolone compounds 3 (R1═H, R2=Me) and 4 (R1═R2=Me), respectively;
(c) treating ethyl piperazine-1-carboxylate with 4-nitrophenyl chloroformate and triethylamine (Et3N) to give an intermediate compound of activated carbamate;
(d) treating the activated carbamate with benzothiazolone (compound 1) in 4-dimethylaminopyridine (DMAP) and diisopropylethylamine (DIEA) to give compound 5;
(e) treating benzothiazolone 1 (or pyridinothiazolone 4) with methyl 2-bromoacetate in the presence of DIEA and cesium carbonate (Cs2CO3) to give compounds 6 and 7, respectively;
(f) treating compounds 6 and 7 in concentrated hydrochloric acid at 100° C. to give compounds 8 and 9, respectively;
(g) treating benzothiazolone 1 (or pyridinothiazolone 4) with appropriate halides in the presence of Et3N and Cs2CO3 to give compounds 11, 12, 19, 21 and 22;
(h) treating tert-butyl carbamate 12 and 22 with trifluoroacetic acid (TFA) to give compounds 10 and 20, respectively;
(i) treating compound 10 with benzyl chloroformate in the presence of DIEA to give compound 13;
(j) treating compound 10 with 4-nitrophenyl chlorformate in the presence of DMAP to give compound 14;
(k) treating compound 10 with allyl bromide in the presence of DIEA to give compound 15;
(l) treating tert-buty; 4-(2-chloroacetyl)piperazine-1-carboxylate with sodium iodide in acetone to give the corresponding iodo compound, tert-butyl 4 (2-iodoacetyl)piperazine-1-carboxylate;
(m) treating saccharin (compound 2) with the above-prepared iodo compound in the presence of DIEA to give compound 17;
(n) treating tert-butyl carbamate 17 with TFA to give compound 16;
(o) treating phthalimide with tert-butyl 4-(2-chloroacetyl)piperazine-1-carboxylate in the presence of tetrabutylammonium iodide (TBAI) and DIEA to give compound 18;
(p) treating compound 9 with ethyl piperazine-1-carboxylate in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), DMAP and DIEA to give compound 21 (YMU1);
(q) treating benzothiazolone 1 with ethyl 4(4-iodobutanoyl)piperazine-1-carboxylate in the presence of DIEA to give compound 23;
(r) treating benzothiazolone 1 with 1,1′-(piperazine-1,4-diyl)-bis(2-iodoethanone) in the presence of DIEA to give compound 24;
(s) treating pyridinothiazolone 4 with methyl 2-bromoacetate in the presence of DIEA and Cs2CO3 to give N-alkylation compound 7 and O-alkylation compound 25;
(t) treating compound 25 in concentrated hydrochloric acid at 100° C. to give compound 26, or
(u) treating compound 26 with morpholine (or ethyl piperazine-1-carboxylate) in the presence of EDCI, DMAP and DIEA to give compounds 27 and 28, respectively.

### Claim 34 (depends on 1)

A method of sensitizing cancer cells to radiation therapy, chemotherapy or immunomodulatory therapy comprising exposing the cancer cells to an effective amount of a composition of claim 1.

### Claim 35 (depends on 34)

The method of claim 34, wherein said composition selectively targets toxicity to cancer cells with DNA lesions.

### Claim 36 (depends on 34)

The method of claim 34, wherein said. composition does not result in genotoxic side effects.

### Claim 37 (depends on 34)

The method of claim 34, wherein said chemotherapy involves treatment with doxorubicin.

### Claim 38

A method for sensitizing cancer cells to the therapeutic effects of radiation therapy, chemotherapy or immunomodulatory therapy comprising exposing the cancer cells to an effective amount of an agent that inhibits TMPK activity.

### Claim 39 (depends on 1, 38)

The method of claim 38, wherein said agent is a composition. of any of claim 1.

### Claim 40 (depends on 1)

A method of preventing double-strand break repair of cancer cells comprising exposing the cancer cells to an effective amount of a composition of claim 1.

### Claim 41 (depends on 1)

A method of selectively targeting toxicity to cancer cells with DNA lesions comprising exposing the cancer cells to an effective amount of a composition of claim 1.

### Claim 42 (depends on 34)

The method of claim 34, wherein said cancer cell is selected from the group consisting of a breast cancer cell, a hepatoma cell, a colorectal cancer cell, pancreatic carcinoma cell, an esophageal carcinoma cell, a bladder cancer cell, an ovarian cancer cell, a skin cancer cell, a liver carcinoma cell, a gastric cancer cell, a prostate cancer cell, a colon cancer cell, a lung cancer cell, a rectal cancer cell, a renal cancer cell, a thyroid cancer cell, a brain cancer cell, melanoma, sarcoma, leukemia, a bone cancer cell, and endometrial cancer cell.

### Claim 43 (depends on 34)

The method of claim 34, further comprising exposing the cancer cells to at least one additional therapeutic agent selected from the group consisting of anticancer agents, antiviral agents, anti-inflammatory agents and immunosuppressive agents.

### Claim 44 (depends on 1)

A method of treating or preventing cancer in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a composition of claim 1.

### Claim 45 (depends on 44)

The method of claim 44, wherein said composition selectively targets toxicity to cancer cells with DNA lesions.

### Claim 46 (depends on 44)

The method of claim 44, wherein said composition does not result in genotoxic side effects.

### Claim 47 (depends on 44)

The method of claim 44, wherein said composition is administered via inhalation, nasal spray, aerosol spray, orally, intravenously, intraperitoneally, subcutaneously, via a sustained-release delivery system or combinations thereof.

### Claim 48 (depends on 44)

The method of claim 44, further comprising administering at least one additional anti-cancer therapy selected from the group consisting of radiation therapy, chemotherapy or immunomodulatory therapy.

### Claim 49 (depends on 48)

The method of claim 48, wherein said anti-cancer therapy is administered prior to administration of said composition.

### Claim 50 (depends on 48)

The method of claim 48, wherein said anti-cancer therapy is administered simultaneously with administration of said composition.

### Claim 51 (depends on 44)

The method of claim 44, wherein said cancer is selected from the group consisting of breast cancer, hepatoma, colorectal cancer, pancreatic carcinoma, esophageal carcinoma, bladder cancer, ovarian cancer, skin cancer, liver carcinoma, gastric cancer, prostate cancer, colon cancer, lung cancer, rectal cancer, renal cancer, thyroid cancer, brain cancer, melanoma, sarcoma, leukemia, bone cancer and endometrial cancer.

### Claim 52 (depends on 44)

The method of claim 44, wherein said subject is a mammal.
